Indobufen versus dipyridamole plus aspirin in the treatment of patients with peripheral atherosclerotic disease

F. Fabris, A. Steffan, M. L. Randi, G. Avruscio, I. Cordiano, A. Girolami

Research output: Contribution to journalArticle

Abstract

Twenty-seven patients with peripheral atherosclerotic disease were randomized into two therapy regimens consisting of indobufen (Indo) (400 mg/day) and dipyridamole (Dip) (225 mg/day) plus acetylsalicylic acid (ASA) (1 g/day), respectively. Maximal walking distance (MWD) and ankle-arm systolic pressure ratios were measured before and after three and six months of therapy; bleeding time, β-thromboglobulin (β-TG), platelet factor 4 (PF4) and serum thromboxane B2 (TXB2) were also assessed. The two treatment groups showed a significant and progressive increase in pain-free walking distance at both three and six months of therapy, but patients taking indobufen showed a greater improvement. On the contrary, the pressure doppler ratio at rest was statistically improved only in the ASA plus Dip group. Basal β-TG and PF4 levels were normal and no changes occurred during the study in either group, while in all patients bleeding times showed a significant increase above basal values and serum TBX2 decreased.

Original languageEnglish
Pages (from-to)81-92
Number of pages12
JournalJournal of Medicine
Volume23
Issue number2
Publication statusPublished - 1992

Fingerprint

Dipyridamole
Aspirin
Platelet Factor 4
Bleeding Time
Walking
Thromboxane B2
Therapeutics
Serum
Ankle
Arm
Blood Pressure
Pressure
indobufen

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Indobufen versus dipyridamole plus aspirin in the treatment of patients with peripheral atherosclerotic disease. / Fabris, F.; Steffan, A.; Randi, M. L.; Avruscio, G.; Cordiano, I.; Girolami, A.

In: Journal of Medicine, Vol. 23, No. 2, 1992, p. 81-92.

Research output: Contribution to journalArticle

Fabris, F, Steffan, A, Randi, ML, Avruscio, G, Cordiano, I & Girolami, A 1992, 'Indobufen versus dipyridamole plus aspirin in the treatment of patients with peripheral atherosclerotic disease', Journal of Medicine, vol. 23, no. 2, pp. 81-92.
Fabris, F. ; Steffan, A. ; Randi, M. L. ; Avruscio, G. ; Cordiano, I. ; Girolami, A. / Indobufen versus dipyridamole plus aspirin in the treatment of patients with peripheral atherosclerotic disease. In: Journal of Medicine. 1992 ; Vol. 23, No. 2. pp. 81-92.
@article{6f256542e68d4301b374cf0515728591,
title = "Indobufen versus dipyridamole plus aspirin in the treatment of patients with peripheral atherosclerotic disease",
abstract = "Twenty-seven patients with peripheral atherosclerotic disease were randomized into two therapy regimens consisting of indobufen (Indo) (400 mg/day) and dipyridamole (Dip) (225 mg/day) plus acetylsalicylic acid (ASA) (1 g/day), respectively. Maximal walking distance (MWD) and ankle-arm systolic pressure ratios were measured before and after three and six months of therapy; bleeding time, β-thromboglobulin (β-TG), platelet factor 4 (PF4) and serum thromboxane B2 (TXB2) were also assessed. The two treatment groups showed a significant and progressive increase in pain-free walking distance at both three and six months of therapy, but patients taking indobufen showed a greater improvement. On the contrary, the pressure doppler ratio at rest was statistically improved only in the ASA plus Dip group. Basal β-TG and PF4 levels were normal and no changes occurred during the study in either group, while in all patients bleeding times showed a significant increase above basal values and serum TBX2 decreased.",
author = "F. Fabris and A. Steffan and Randi, {M. L.} and G. Avruscio and I. Cordiano and A. Girolami",
year = "1992",
language = "English",
volume = "23",
pages = "81--92",
journal = "Journal of Medicine",
issn = "0025-7850",
publisher = "S. Karger AG",
number = "2",

}

TY - JOUR

T1 - Indobufen versus dipyridamole plus aspirin in the treatment of patients with peripheral atherosclerotic disease

AU - Fabris, F.

AU - Steffan, A.

AU - Randi, M. L.

AU - Avruscio, G.

AU - Cordiano, I.

AU - Girolami, A.

PY - 1992

Y1 - 1992

N2 - Twenty-seven patients with peripheral atherosclerotic disease were randomized into two therapy regimens consisting of indobufen (Indo) (400 mg/day) and dipyridamole (Dip) (225 mg/day) plus acetylsalicylic acid (ASA) (1 g/day), respectively. Maximal walking distance (MWD) and ankle-arm systolic pressure ratios were measured before and after three and six months of therapy; bleeding time, β-thromboglobulin (β-TG), platelet factor 4 (PF4) and serum thromboxane B2 (TXB2) were also assessed. The two treatment groups showed a significant and progressive increase in pain-free walking distance at both three and six months of therapy, but patients taking indobufen showed a greater improvement. On the contrary, the pressure doppler ratio at rest was statistically improved only in the ASA plus Dip group. Basal β-TG and PF4 levels were normal and no changes occurred during the study in either group, while in all patients bleeding times showed a significant increase above basal values and serum TBX2 decreased.

AB - Twenty-seven patients with peripheral atherosclerotic disease were randomized into two therapy regimens consisting of indobufen (Indo) (400 mg/day) and dipyridamole (Dip) (225 mg/day) plus acetylsalicylic acid (ASA) (1 g/day), respectively. Maximal walking distance (MWD) and ankle-arm systolic pressure ratios were measured before and after three and six months of therapy; bleeding time, β-thromboglobulin (β-TG), platelet factor 4 (PF4) and serum thromboxane B2 (TXB2) were also assessed. The two treatment groups showed a significant and progressive increase in pain-free walking distance at both three and six months of therapy, but patients taking indobufen showed a greater improvement. On the contrary, the pressure doppler ratio at rest was statistically improved only in the ASA plus Dip group. Basal β-TG and PF4 levels were normal and no changes occurred during the study in either group, while in all patients bleeding times showed a significant increase above basal values and serum TBX2 decreased.

UR - http://www.scopus.com/inward/record.url?scp=0026713064&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026713064&partnerID=8YFLogxK

M3 - Article

C2 - 1512524

AN - SCOPUS:0026713064

VL - 23

SP - 81

EP - 92

JO - Journal of Medicine

JF - Journal of Medicine

SN - 0025-7850

IS - 2

ER -